

# Jeffrey Seow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7526794/publications.pdf>

Version: 2024-02-01

29  
papers

4,005  
citations

394390

19  
h-index

477281

29  
g-index

47  
all docs

47  
docs citations

47  
times ranked

10898  
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , 2020, 5, 1598-1607.	13.3	1,115
2	A dynamic COVID-19 immune signature includes associations with poor prognosis. <i>Nature Medicine</i> , 2020, 26, 1623-1635.	30.7	765
3	Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. <i>Lancet Oncology</i> , The, 2021, 22, 765-778.	10.7	491
4	Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. <i>Nature Medicine</i> , 2020, 26, 1701-1707.	30.7	315
5	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890.	6.4	200
6	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	14.3	112
7	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. <i>Science Advances</i> , 2021, 7, .	10.3	107
8	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020, 16, e1008817.	4.7	105
9	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	13.3	94
10	The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate. <i>Nature Immunology</i> , 2021, 22, 1490-1502.	14.5	65
11	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. <i>Journal of Infection</i> , 2020, 81, 931-936.	3.3	59
12	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T cell responses in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 999-1006.	2.5	55
13	A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25057-25067.	7.1	53
14	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. <i>Leukemia</i> , 2021, 35, 3573-3577.	7.2	41
15	SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. <i>ELife</i> , 2022, 11, .	6.0	34
16	Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer. <i>Cancer Cell</i> , 2021, 39, 1445-1447.	16.8	29
17	Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. <i>MBio</i> , 2022, 13, e0379821.	4.1	28
18	Disordered epitopes as peptide vaccines. <i>Peptide Science</i> , 2018, 110, e24067.	1.8	23

#	ARTICLE	IF	CITATIONS
19	Structural basis for epitope masking and strain specificity of a conserved epitope in an intrinsically disordered malaria vaccine candidate. <i>Scientific Reports</i> , 2015, 5, 10103.	3.3	21
20	Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein. <i>ELife</i> , 2020, 9, .	6.0	19
21	ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type composition—implications for COVID-19. <i>International Journal of Obesity</i> , 2022, 46, 1478-1486.	3.4	18
22	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	6.4	10
23	Lipid interactions modulate the structural and antigenic properties of the C-terminal domain of the malaria antigen merozoite surface protein 2. <i>FEBS Journal</i> , 2017, 284, 2649-2662.	4.7	8
24	Contrasting Modes of New World Arenavirus Neutralization by Immunization-Elicited Monoclonal Antibodies. <i>MBio</i> , 2022, 13, e0265021.	4.1	7
25	Transient antibody-antigen interactions mediate the strain-specific recognition of a conserved malaria epitope. <i>Communications Biology</i> , 2018, 1, 58.	4.4	6
26	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. <i>PLoS ONE</i> , 2021, 16, e0249791.	2.5	6
27	Guiding the Immune Response to a Conserved Epitope in MSP2, an Intrinsically Disordered Malaria Vaccine Candidate. <i>Vaccines</i> , 2021, 9, 855.	4.4	2
28	Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2. <i>Vaccine</i> , 2021, 39, 1746-1757.	3.8	1
29	Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients. <i>Blood</i> , 2021, 138, 3920-3920.	1.4	1